Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) from a sell rating to a hold rating in a research report released on Saturday.

Separately, HC Wainwright raised Unicycive Therapeutics to a “strong-buy” rating and set a $90.00 target price on the stock in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to data from MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Get Our Latest Report on Unicycive Therapeutics

Unicycive Therapeutics Trading Down 0.2%

Shares of NASDAQ UNCY opened at $4.19 on Friday. Unicycive Therapeutics has a twelve month low of $2.83 and a twelve month high of $11.00. The stock has a 50 day moving average of $4.64 and a two-hundred day moving average of $5.57. The stock has a market cap of $74.00 million, a P/E ratio of -1.02 and a beta of 1.87.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.18. As a group, research analysts predict that Unicycive Therapeutics will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics during the second quarter worth $55,000. JPMorgan Chase & Co. grew its holdings in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares during the period. Vivo Capital LLC grew its holdings in Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock valued at $6,537,000 after purchasing an additional 1,400,000 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in Unicycive Therapeutics by 16.8% in the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock valued at $7,942,000 after purchasing an additional 1,441,000 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after purchasing an additional 34,183 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Featured Stories